Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
By G. De Luca, H. Suryapranata, Gregg Stone, D. Antoniucci, J. Tcheng, F. Neumann, F. Van de Werf, E. Antman, Eric J. Topol. Journal of the American Medical Association (JAMA), 2005
622 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/dac979b481946660696ebd11c3a6b0b567073380
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Pathology and Forensic Medicine
Citations in the corpus
- Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. (2008, background): “A systematic review of these trials showed that abciximab reduced 30-day mortality by 32% without affecting the risk of haemorrhagic stroke and major bleeding.(55) Abciximab did not have a significant impact on the patency of infarct-related vessels, and its administration upstream of a planned PCI ”